LIGAND PHARMACEUTICALS INCORPORATED Deferred Tax Assets, Operating Loss Carryforwards
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) had Deferred Tax Assets, Operating Loss Carryforwards of $32.51 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-27
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $32.51M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $40.38M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $45.70M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $53.96M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $32.51M 10-K · filed 2026-02-27 | |
| 2024-12-31 | $40.38M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $45.70M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $53.96M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $63.47M 10-K · filed 2023-02-28 | $64.35M 10-K · filed 2022-02-28 |
| 2020-12-31 | $64.15M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $150.73M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $57.18M 10-K · filed 2020-02-27 | |
| 2017-12-31 | $90.27M 10-K · filed 2019-02-28 | |
| 2016-12-31 | $150.23M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $160.59M 10-K · filed 2017-02-28 | $188.08M 10-K · filed 2016-02-26 |
| 2014-12-31 | $193.75M 10-K · filed 2016-11-14 | $196.42M 10-K · filed 2014-12-01 |
| 2013-12-31 | $196.42M 10-K · filed 2015-02-23 | |
| 2012-12-31 | $198.44M 10-K/A · filed 2014-12-12 | |
| 2011-12-31 | $164.05M 10-K · filed 2013-03-14 |